GENOMICS & BIOINFORMATICS SHARED RESOURCE (G&BSR) The Genomics & Bioinformatics Shared Resource (G&BSR) is a state-of-the-art facility that has continued to evolve over the past 20 years, providing Cancer Consortium members with access to sophisticated, genomics- based technologies and a team consisting of a highly experienced scientist, expert technical staff, and seasoned bioinformaticians. This team provides a seamless experience for the researcher, supporting all phases of technology selection, experimental design, sample QC, data generation, and analysis. The broad portfolio of massively parallel deep sequencing services offered through the G&BSR includes whole genome sequencing; whole exome sequencing; expression profiling of mRNAs, miRNAs, and non-coding RNAs; ribosome sequencing; and numerous targeted resequencing applications. Additionally, epigenomics services including the profiling of the DNA methylome, ATAC-seq, and Hi-C sequencing assays are performed. The G&BSR was also an early adopter of CRISPR-Cas9 pooled screens and supported the development of CUT&RUN ? a protein-DNA interaction assay developed by Fred Hutch investigators, led by Dr. Steven Henikoff CBB, with both technologies now implemented as high-throughput pipelines available to the broader Consortium community through the G&BSR. In addition, the G&BSR routinely employs NanoString digital barcoding technology, conducts Sanger sequencing, and provides training on and access to qPCR instrumentation. Major equipment includes an Illumina NovaSeq 6000 sequencer, an lllumina HiSeq 2500 sequencer, two Illumina MiSeq sequencers, a Pacific Biosciences Sequel sequencer, an Illumina BeadChip system, a NanoString nCounter system, a 10x Genomics Chromium controller, two ABI 3730xl sequencers, a PerkinElmer Sciclone NGSx Workstation, and four ThermoFisher Scientific QuantStudio 5 real-time PCR systems. Peer-reviewed studies accounted for 66% of the work performed in the G&BSR during 2017 and staff contributed to over 30 publications (July 2017 ? June 2018).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-46
Application #
10125955
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications